{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:02:43Z","timestamp":1789516963770,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":79,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infections are major public health issues throughout the world. In resource-limited areas, successful treatment of HCV\/HIV coinfection frequently faces challenges, particularly restricted access to drugs and poor treatment compliance. However, data comparing single-tablet regimen (STR) versus multi-tablet regimen (MTR) direct-acting antiviral (DAA) strategies, specifically focusing on pill burden, remain scarce in such settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center, retrospective cohort study enrolled patients with HCV\/HIV coinfection between April 2023 and October 2025. All patients received DAA therapy in addition to the antiretroviral therapy (ART). Participants were divided into DAA STR (one pill daily) and DAA MTR (multiple pills daily) groups. The primary endpoint was sustained virologic response at least 12 weeks after completion of treatment (SVR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 105 patients with HCV\/HIV coinfection were enrolled. The overall SVR rate was 96.2% (101\/105). The DAA STR group had a numerically higher SVR rate than the DAA MTR group (98.8% vs. 88.0%,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.041); however, this comparison was confounded by genotype. In a sensitivity analysis limited to non-genotype 3b patients (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200987), SVR rate was 98.8% in the DAA STR group and 85.7% in the DAA MTR group (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.155). The DAA STR demonstrated a numerical advantage in achieving SVR in all subgroups stratified by sex, age, HCV infection route, baseline HCV RNA level, HCV genotype, and ART regimen. Univariate logistic regression identified DAA regimen was the only factor associated with SVR (OR 10.773, 95% CI 1.067\u2013108.743); however, because only 4 participants failed to achieve SVR, this analysis was exploratory and the estimate was statistically unstable.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this real-world study, both DAA STR and DAA MTR achieved high overall SVR rates in HCV\/HIV coinfection in a resource-limited setting. The simplified DAA STR was associated with a numerically higher SVR, but the comparison was confounded by the selective allocation of genotype 3b patients to DAA MTR. The observed difference between DAA STR and DAA MTR may reflect treatment selection practices and genotype distribution rather than an independent effect of regimen simplification. The simplified pill count-based strategy remains a practical option, but its advantage over MTR was confounded by genotype selection in this cohort. Our findings support the feasibility of both approaches and highlight the need for large, prospective, genotype-balanced comparative studies with integrated adherence monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-026-13895-2","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T07:47:56Z","timestamp":1782719276000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A real-world study of the efficacy of a simplified pill count-based strategy for treating HCV\/HIV coinfection patients"],"prefix":"10.1186","volume":"26","author":[{"given":"Bianchuan","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cunliang","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongsheng","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"issue":"1","key":"13895_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1146\/annurev-med-050223-111239","volume":"76","author":"RL Fleurence","year":"2025","unstructured":"Fleurence RL, Alter HJ, Collins FS, Ward JW. Global elimination of hepatitis C virus. Annu Rev Med. 2025;76(1):29\u201341.","journal-title":"Annu Rev Med"},{"issue":"2","key":"13895_CR2","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/nrgastro.2016.176","volume":"14","author":"AP Thrift","year":"2017","unstructured":"Thrift AP, El-Serag HB, Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol. 2017;14(2):122\u201332.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"11","key":"13895_CR3","doi-asserted-by":"publisher","first-page":"6597","DOI":"10.3390\/ijerph19116597","volume":"19","author":"EA Armstrong-Mensah","year":"2022","unstructured":"Armstrong-Mensah EA, Tetteh AK, Ofori E, Ekhosuehi O. Voluntary counseling and testing, antiretroviral therapy access, and HIV-related stigma: Global progress and challenges. Int J Environ Res Public Health. 2022;19(11):6597.","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"13895_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12981-025-00745-5","volume":"22","author":"YF Chen","year":"2025","unstructured":"Chen YF, Li AD, Yang YZ, Lu J, Xu Y, Ji XY, et al. Global, regional and national burden of HIV\/AIDS among individuals aged 15\u201379 from 1990 to 2021. AIDS Res Ther. 2025;22(1):51.","journal-title":"AIDS Res Ther"},{"issue":"1","key":"13895_CR5","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1089\/aid.2021.0197","volume":"39","author":"RQ Ferrufino","year":"2023","unstructured":"Ferrufino RQ, Bierrenbach AL, Rodrigues C, Figueiredo GM, Gleison D, Yapura S, et al. The changing epidemiology of hepatitis C virus acquisition among HIV-infected individuals in Brazil. AIDS Res Hum Retroviruses. 2023;39(1):44\u20139.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"13895_CR6","doi-asserted-by":"publisher","first-page":"e261","DOI":"10.1017\/S0950268819001365","volume":"147","author":"AM Zhang","year":"2019","unstructured":"Zhang AM, Yang M, Gao L, Zhang M, Jiao LS, Feng Y, et al. The distinct epidemic characteristics of HCV co-infection among HIV-1-infected population caused by drug injection and sexual transmission in Yunnan, China. Epidemiol Infect. 2019;147:e261.","journal-title":"Epidemiol Infect"},{"issue":"7","key":"13895_CR7","doi-asserted-by":"publisher","first-page":"e101241","DOI":"10.1371\/journal.pone.0101241","volume":"9","author":"CT Dong","year":"2014","unstructured":"Dong CT, Huang ZJ, Martin MC, Huang J, Liu HL, Deng B, et al. The impact of social factors on human immunodeficiency virus and hepatitis C virus co-infection in a minority region of Si-Chuan, the People\u2019s Republic of China: A population-based survey and testing study. PLoS ONE. 2014;9(7):e101241.","journal-title":"PLoS ONE"},{"issue":"1","key":"13895_CR8","doi-asserted-by":"publisher","first-page":"11301","DOI":"10.1038\/s41598-021-90706-5","volume":"11","author":"LY Chen","year":"2021","unstructured":"Chen LY, Du LY, Kang S, Ma FH, Li CM, He M, et al. Sofosbuvir plus Ribavirin is effective for HCV elimination in people living with HIV from rural area of China. Sci Rep. 2021;11(1):11301.","journal-title":"Sci Rep"},{"issue":"48","key":"13895_CR9","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.46234\/ccdcw2021.250","volume":"3","author":"ZF Liu","year":"2021","unstructured":"Liu ZF, Tang XF, Liu YF, Zhang LL, Yang YH, Zheng YL, et al. HIV prevention and health poverty alleviation - Liangshan Prefecture, Sichuan Province, China, 2017\u20132020. China CDC Wkly. 2021;3(48):1031\u20135.","journal-title":"China CDC Wkly"},{"key":"13895_CR10","doi-asserted-by":"publisher","first-page":"320532","DOI":"10.1155\/2015\/320532","volume":"2015","author":"MC Liberto","year":"2015","unstructured":"Liberto MC, Zicca E, Pavia G, Quirino A, Marascio N, Torti C, et al. Virological mechanisms in the coinfection between HIV and HCV. Mediators Inflamm. 2015;2015:320532.","journal-title":"Mediators Inflamm"},{"issue":"4","key":"13895_CR11","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1002\/hep.23136","volume":"50","author":"J Mac\u00edas","year":"2009","unstructured":"Mac\u00edas J, Berenguer J, Jap\u00f3n MA, Gir\u00f3n JA, Rivero A, L\u00f3pez-Cort\u00e9s LF, et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus\/hepatitis C virus. Hepatology. 2009;50(4):1056\u201363.","journal-title":"Hepatology"},{"issue":"4","key":"13895_CR12","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1086\/321909","volume":"33","author":"CS Graham","year":"2001","unstructured":"Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: A meta-analysis. Clin Infect Dis. 2001;33(4):562\u20139.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"13895_CR13","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1002\/hep.29642","volume":"67","author":"C Sikavi","year":"2018","unstructured":"Sikavi C, Chen PH, Lee AD, Saab EG, Choi G, Saab S. Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population. Hepatology. 2018;67(3):847\u201357.","journal-title":"Hepatology"},{"issue":"1","key":"13895_CR14","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/14656566.2017.1419185","volume":"19","author":"S Schlabe","year":"2018","unstructured":"Schlabe S, Rockstroh JK. Advances in the treatment of HIV\/HCV coinfection in adults. Expert Opin Pharmacother. 2018;19(1):49\u201364.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"13895_CR15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.tips.2021.10.004","volume":"43","author":"L Men\u00e9ndez-Arias","year":"2022","unstructured":"Men\u00e9ndez-Arias L, Delgado R. Update and latest advances in antiretroviral therapy. Trends Pharmacol Sci. 2022;43(1):16\u201329.","journal-title":"Trends Pharmacol Sci"},{"issue":"9534","key":"13895_CR16","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S0140-6736(06)69157-5","volume":"368","author":"V Simon","year":"2006","unstructured":"Simon V, Ho DD, Abdool Karim Q. HIV\/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet. 2006;368(9534):489\u2013504.","journal-title":"Lancet"},{"issue":"1","key":"13895_CR17","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12879-024-09048-y","volume":"24","author":"L Yuan","year":"2024","unstructured":"Yuan L, Chen KY, Cai YF, Zhou ZH, Yang J, Jiqu WT, et al. Analysis of ART effects and drug resistance in adult HIV\/AIDS patients in Meigu County, Liangshan Prefecture, China. BMC Infect Dis. 2024;24(1):155.","journal-title":"BMC Infect Dis"},{"issue":"11","key":"13895_CR18","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1080\/03007995.2019.1643160","volume":"35","author":"JJ An","year":"2019","unstructured":"An JJ, Lee JS, Sharpsten L, Wilson AK, Cao F, Tran JN. Impact of pill burden on adherence to hepatitis C medication. Curr Med Res Opin. 2019;35(11):1937\u201344.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"13895_CR19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2174\/011570162X307740240604115154","volume":"22","author":"M Simon","year":"2024","unstructured":"Simon M, Derrick S, Kosanam S, Pasupula R. Pill burden: A major barrier to HAART adherence and fixed dose combinations (FDCS) as its solution - A mini-review. Curr HIV Res. 2024;22(3):143\u201352.","journal-title":"Curr HIV Res"},{"issue":"Suppl 3","key":"13895_CR20","first-page":"24S","volume":"33","author":"J Cutrell","year":"2016","unstructured":"Cutrell J, Bedimo R. Single-tablet regimens in the treatment of HIV-1 infection. Fed Pract. 2016;33(Suppl 3):S24\u201330.","journal-title":"Fed Pract"},{"issue":"4 Suppl 3","key":"13895_CR21","doi-asserted-by":"publisher","first-page":"19537","DOI":"10.7448\/IAS.17.4.19537","volume":"17","author":"D Sweet","year":"2014","unstructured":"Sweet D, Song JL, Zhong YC, Signorovitch J. Real-world medication persistence with single versus multiple tablet regimens for HIV-1 treatment. J Int AIDS Soc. 2014;17(4 Suppl 3):19537.","journal-title":"J Int AIDS Soc"},{"key":"13895_CR22","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2147\/PPA.S192735","volume":"13","author":"F Altice","year":"2019","unstructured":"Altice F, Evuarherhe O, Shina S, Carter G, Beaubrun AC. Adherence to HIV treatment regimens: systematic literature review and meta-analysis. Patient Prefer Adherence. 2019;13:475\u201390.","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"13895_CR23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1185\/03007995.2013.844685","volume":"30","author":"I Aldir","year":"2014","unstructured":"Aldir I, Horta A, Serrado M. Single-tablet regimens in HIV: Does it really make a difference? Curr Med Res Opin. 2014;30(1):89\u201397.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"13895_CR24","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1177\/1060028016682531","volume":"51","author":"JC Sebaaly","year":"2017","unstructured":"Sebaaly JC, Kelley D. Single-tablet regimens for the treatment of HIV-1 infection. Ann Pharmacother. 2017;51(4):332\u201344.","journal-title":"Ann Pharmacother"},{"key":"13895_CR25","unstructured":"World Health Organization. Updated recommendations on HCV simplified service delivery and HCV diagnostics: Policy brief. https:\/\/www.who.int\/publications\/i\/item\/9789240052697. (Accessed November 21, 2025)."},{"key":"13895_CR26","first-page":"100749","volume":"36","author":"WY Lin","year":"2023","unstructured":"Lin WY, Wang XC, Zhang JB, Wen CY, Kang W, Mao L, et al. A simple, feasible, efficient and safe treatment strategy of sofosbuvir\/velpatasvir for chronic HCV\/HIV-1 coinfected patients regardless of HCV genotypes: A multicenter, open-label study in China. Lancet Reg Health West Pac. 2023;36:100749.","journal-title":"Lancet Reg Health West Pac"},{"issue":"12","key":"13895_CR27","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1111\/apt.14647","volume":"47","author":"CH Liu","year":"2018","unstructured":"Liu CH, Sun HY, Liu CJ, Sheng WH, Hsieh SM, Lo YC, et al. Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection. Aliment Pharmacol Ther. 2018;47(12):1690\u20138.","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"13895_CR28","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1080\/14656566.2017.1346609","volume":"18","author":"V Soriano","year":"2017","unstructured":"Soriano V, Fernandez-Montero JV, de Mendoza C, Benitez-Gutierrez L, Pe\u00f1a JM, Arias A, et al. Treatment of hepatitis C with new fixed dose combinations. Expert Opin Pharmacother. 2017;18(12):1235\u201342.","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"13895_CR29","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.ijantimicag.2018.12.010","volume":"53","author":"M Bourli\u00e8re","year":"2019","unstructured":"Bourli\u00e8re M, Pietri O. Hepatitis C virus therapy: No one will be left behind. Int J Antimicrob Agents. 2019;53(6):755\u201360.","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"13895_CR30","first-page":"428","volume":"15","author":"Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association","year":"2022","unstructured":"Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of hepatitis C (2022 version). Chin J Clin Infect Dis. 2022;15(6):428\u201347. (in Chinese).","journal-title":"Chin J Clin Infect Dis"},{"issue":"2","key":"13895_CR31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S2468-1253(18)30343-1","volume":"4","author":"L Wei","year":"2019","unstructured":"Wei L, Lim SG, Xie Q, V\u0103n KN, Piratvisuth T, Huang Y, et al. Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: A single-arm, open-label, phase 3 trial. Lancet Gastroenterol Hepatol. 2019;4(2):127\u201334.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"13895_CR32","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jgar.2023.01.002","volume":"32","author":"MH Chen","year":"2023","unstructured":"Chen MH, Wu M, Zeng LY, Zhang Y, Huobu-Mo M, Li JH, et al. Virologic status and pattern of drug resistance mutation among ART-experienced HIV-infected patients in Butuo County, China. J Glob Antimicrob Resist. 2023;32:98\u2013103.","journal-title":"J Glob Antimicrob Resist"},{"issue":"4","key":"13895_CR33","first-page":"299","volume":"37","author":"WQ Deng","year":"2024","unstructured":"Deng WQ, Meng CL, Feng P, Chen LY, Wang Y, Liu K. Analysis of influential factors of antiretroviral therapy failure for AIDS among Yi people in Liangshan Prefecture. Infect Dis Info. 2024;37(4):299\u2013304. (in Chinese).","journal-title":"Infect Dis Info"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13895-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13895-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13895-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:18:58Z","timestamp":1789514338000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13895-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13895"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13895-2","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"28 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Helsinki Declaration as revised in 2024 and approved by the Medical Ethics Committee of the First People\u2019s Hospital of Yuexi County (No. KY202511-01). The requirement for informed consent to participate was waived by this Medical Ethics Committee because the study was retrospective and used fully anonymized data, in accordance with regulations.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This retrospective study was based on fully anonymized data that were de-identified before analysis. The manuscript contains no personal identifiers, images, or clinical details that could compromise anonymity. Accordingly, the Medical Ethics Committee of the First People\u2019s Hospital of Yuexi County (No. KY202511-01) confirmed that written informed consent for publication was not required.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1657"}}